公开(公告)号：US07749994B2

公开(公告)日：2010-07-06

申请号：US11503405

申请日：2006-08-14

Applicant: Thomas E. Rawson ,  Brian Safina ,  Jennafer Dotson ,  Aihe Zhou ,  Ignacio Aliagas-Martin ,  Jason Halladay ,  Jun Liang ,  Matthias Rueth ,  Bing-Yan Zhu ,  Frederick Brookfield ,  Michael Prime ,  Birong Zhang ,  Jun M. Li

Inventor： Thomas E. Rawson ,  Brian Safina ,  Jennafer Dotson ,  Aihe Zhou ,  Ignacio Aliagas-Martin ,  Jason Halladay ,  Jun Liang ,  Matthias Rueth ,  Bing-Yan Zhu ,  Frederick Brookfield ,  Michael Prime ,  Birong Zhang ,  Jun M. Li

IPC: A61K31/55 ,  A61K31/538 ,  A61K31/424 ,  A61K31/4188 ,  C07D498/22

CPC classification number: C07D487/04 ,  C07D491/04

Abstract: The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula I wherein A, X, Y, Z, Ra, Rb, Rc, R1, R2, R3 and m are defined herein.

Abstract translation: 本发明提供新的激酶抑制剂，其可用作例如治疗恶性肿瘤的治疗剂，其中化合物具有通式I，其中A，X，Y，Z，R a，R b，R c，R 1，R 2，R 3和m定义 这里。

公开(公告)号：US20090304904A1

公开(公告)日：2009-12-10

申请号：US12455615

申请日：2009-06-04

Applicant: Ian David Lacy ,  Blake Michael Prime

Inventor： Ian David Lacy ,  Blake Michael Prime

IPC: A23G9/44 ,  A23G9/04 ,  A23P1/00

CPC classification number: A23G9/48

Abstract: A frozen confection product having a thickness of less than 40 mm, and comprising from 25 to 70 wt % of transparent ice particles having a mean size of from 2 to 30 mm is provided. A process for producing the frozen confection is also provided.

Abstract translation: 提供厚度小于40mm的冷冻甜食产品，并且包含25至70重量％的平均尺寸为2至30mm的透明冰颗粒。 还提供了一种生产冷冻甜食的方法。

公开(公告)号：US20160251318A1

公开(公告)日：2016-09-01

申请号：US14241374

申请日：2012-08-28

Applicant: Stephen Martin Courtney ,  Michael Prime ,  William Mitchell ,  Christopher John Brown ,  Paula C. De Aguiar Pena ,  Peter Johnson ,  Celia Dominguez ,  Leticia M. Toledo-Sherman ,  Ignacio Munoz

Inventor： Stephen Martin Courtney ,  Michael Prime ,  William Mitchell ,  Christopher John Brown ,  Paula C. De Aguiar Pena ,  Peter Johnson ,  Celia Dominguez ,  Leticia M. Toledo-Sherman ,  Ignacio Munoz

IPC: C07D239/28 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D401/12 ,  C07D405/04 ,  C07D491/048 ,  C07D491/052 ,  C07H13/10 ,  C07D413/04 ,  C07D471/04 ,  C07D409/04 ,  C07D417/04 ,  C07D403/10 ,  C07D405/10 ,  C07D401/04

CPC classification number: C07D239/28 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D491/048 ,  C07D491/052 ,  C07H13/10

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract translation: 本文提供了某些化学实体。 还提供了包含至少一种化学物质和一种或多种药学上可接受的载体的药物组合物。 描述了治疗患有对KMO活性的抑制作用的某些疾病和病症的患者的方法，其包括给予这些患者一定量的至少一种有效减少疾病或病症的体征或症状的化学实​​体。 这些疾病包括神经变性疾病如亨廷顿氏病。 还描述了治疗方法，包括给予至少一种作为单一活性剂的化学实体或与一种或多种其它治疗剂组合施用至少一种化学实体。 还提供了用于筛选能够抑制KMO活性的化合物的方法。

公开(公告)号：US07939532B2

公开(公告)日：2011-05-10

申请号：US12377911

申请日：2006-10-24

Applicant: Frederick Brookfield ,  Jonathan Gridley ,  Lothar Kling ,  Michael Prime ,  Ulrike Reiff ,  Wolfgang Von Der Saal ,  Thomas Von Hirschheydt

Inventor： Frederick Brookfield ,  Jonathan Gridley ,  Lothar Kling ,  Michael Prime ,  Ulrike Reiff ,  Wolfgang Von Der Saal ,  Thomas Von Hirschheydt

IPC: A61K31/438 ,  A61K31/4545 ,  A61K31/496 ,  C07D213/74 ,  C07D401/12 ,  C07D491/13 ,  A61P35/00

CPC classification number: C07D295/04

Abstract: Objects of the present invention are the compounds of formula I, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.

Abstract translation: 本发明的目的是式I化合物，其药学上可接受的盐，对映体形式，非对映异构体和外消旋体，上述化合物的制备，含有它们的药物及其制备，以及上述化合物在对照中的用途 或预防癌症等疾病。

公开(公告)号：US08946197B2

公开(公告)日：2015-02-03

申请号：US13509783

申请日：2010-11-12

Applicant: Celia Dominguez ,  John Wityak ,  Michael Prime ,  Stephen Martin Courtney ,  Christopher Yarnold ,  Frederick Brookfield ,  Richard Marston ,  Douglas Macdonald

Inventor： Celia Dominguez ,  John Wityak ,  Michael Prime ,  Stephen Martin Courtney ,  Christopher Yarnold ,  Frederick Brookfield ,  Richard Marston ,  Douglas Macdonald

IPC: A61K31/635 ,  C07C311/46 ,  C07D211/34 ,  C07D211/54 ,  C07D211/58 ,  C07D211/96 ,  C07D213/38 ,  C07D213/40 ,  C07D213/56 ,  C07D215/38 ,  C07D217/14 ,  C07D217/22 ,  C07D239/42 ,  C07D263/58 ,  C07D277/42 ,  C07D295/205 ,  C07D295/26 ,  C07D307/52 ,  C07D401/04 ,  C07D487/04 ,  C07D495/04

CPC classification number: C07C311/46 ,  C07C2601/14 ,  C07D211/34 ,  C07D211/54 ,  C07D211/58 ,  C07D211/96 ,  C07D213/38 ,  C07D213/40 ,  C07D213/56 ,  C07D215/38 ,  C07D217/14 ,  C07D217/22 ,  C07D239/42 ,  C07D263/58 ,  C07D277/42 ,  C07D295/205 ,  C07D295/26 ,  C07D307/52 ,  C07D401/04 ,  C07D487/04 ,  C07D495/04

Abstract: Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

Abstract translation: 本文提供了某些化合物和药学上可接受的盐。 还提供了包含至少一种化合物或其药学上可接受的盐的药物组合物和一种或多种药学上可接受的载体。 描述了治疗患有某种疾病状态的患者对抑制转谷氨酰胺酶TG2活性有反应的方法。 这些疾病状态包括神经变性疾病如亨廷顿病。 还描述了治疗方法，包括给予至少一种化合物或其药学上可接受的盐作为单一活性剂，或者与一种或多种其它治疗剂组合施用至少一种化合物或其药学上可接受的盐。

公开(公告)号：US20100292247A1

公开(公告)日：2010-11-18

申请号：US12377911

申请日：2007-10-24

Applicant: Frederick Brookfield ,  Jonathan Gridley ,  Lothar Kling ,  Michael Prime ,  Ulrike Reiff ,  Wolfgang von der Saal ,  Thomas von Hirschheydt

Inventor： Frederick Brookfield ,  Jonathan Gridley ,  Lothar Kling ,  Michael Prime ,  Ulrike Reiff ,  Wolfgang von der Saal ,  Thomas von Hirschheydt

IPC: A61K31/496 ,  C07D401/14 ,  C07D401/04 ,  C07D491/113 ,  A61K31/438 ,  A61P35/00

CPC classification number: C07D295/04

Abstract: Objects of the present invention are the compounds of formula I, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.

Abstract translation: 本发明的目的是式I化合物，其药学上可接受的盐，对映体形式，非对映异构体和外消旋体，上述化合物的制备，含有它们的药物及其制备，以及上述化合物在对照中的用途 或预防癌症等疾病。